Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
The pharmacotherapy of inflammatory bowel diseases (Crohn's disease and ulcerative colitis) has experienced significant progress with the advent of monoclonal antibodies (mABs). As therapeutic proteins, mABs display peculiar pharmacokinetic characteristics that differentiate them from chemical...
Saved in:
Main Authors: | Antonello Di Paolo (Author), Giacomo Luci (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies
by: Yamamoto-Furusho JK
Published: (2017) -
Personalized medicine in Europe: not yet personal enough?
by: Antonello Di Paolo, et al.
Published: (2017) -
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
by: Giacomo Luci, et al.
Published: (2021) -
Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems
by: Annalisa Di Rienzo, et al.
Published: (2024) -
Monoclonal Antibodies as Neurological Therapeutics
by: Panagiotis Gklinos, et al.
Published: (2021)